The FDA now judges your cyber plan before clearance. Your AI agents are in scope.

As of February 2026, the FDA judges your cybersecurity plan before it clears your device — missing artifacts are grounds for immediate rejection. Medical robots and clinical AI run their intelligence on hosts that touch PHI. Governing those hosts is now a premarket reality.

The questions medical robotics teams are actually asking

Healthcare AI is regulated AI on real hosts. Under the new regime, product and security teams keep asking:

• Section 524B makes us a "cyber device." Can we show control over the AI agents on our clinical and lab hosts?
• Where do our agents connect, and can we prove PHI stayed inside policy — without building a conversation warehouse?
• Our Secure Product Development Framework ties into the QMS. Can we generate cybersecurity evidence through controlled processes, not bolt-on appendices?
• A cyber incident here can render a device inoperable and delay care. What stops a rogue agent at runtime?

The landscape: cybersecurity is now premarket, and enforceable

On February 3, 2026 the FDA issued its final guidance, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions — superseding the 2025 version and aligning to the new QMSR. It codifies the Secure Product Development Framework as the expected lifecycle and, critically, scopes postmarket cybersecurity inside premarket review: the FDA now judges the plan before clearance, not just after.

The mandatory premarket deliverables are concrete: a machine-readable SBOM, a threat model with trust-boundary coverage, a vulnerability-management plan, demonstrated patchability, and interface-scoped penetration testing. Missing artifacts are grounds for immediate Refuse-to-Accept rejection.

The reason is patient safety. The FDA notes cyberattacks have already rendered medical devices and hospital networks inoperable, disrupting care and creating potential for clinical harm through delayed diagnosis or treatment. For an autonomous clinical or lab system, the AI host is squarely part of that safety picture.

Where the real risk lives — the AI host that touches PHI

Vantio does not certify medical-device safety or clinical efficacy — those are governed by device regulation and clinical process. We protect the general-purpose Linux compute where AI agents and data pipelines run, and we make governing that compute provable for assessment. Patient data is the crux: where are agents connecting, what PHI are they touching, and can you produce evidence access and actions were controlled — without storing the sensitive conversations themselves.

That last point matters for confidentiality. Vantio records connection and decision metadata — host, process, volume, timing, trace, and the decision — and by design never keeps prompts or completions. You get the audit trail the SPDF assumes without turning every clinical agent session into a PHI liability archive.

How Vantio answers these questions

For a device or health-system team, Optics runs free on clinical and lab hosts and stores no conversation content. Gate redacts protected data and refuses unauthorized destinations. Phantom Engine protects Linux hosts you enroll. Enterprise governance produces the audit trail your assessors can draw on.

What Vantio does — and does not — do

• Does: observe and govern AI and LLM agents on Linux clinical, lab, and device-adjacent hosts you own — recording metadata, never prompts.
• Does: produce connection-and-decision evidence that supports SPDF and QMS documentation and assessment readiness.
• Does not: hold FDA clearance, HIPAA, or any certification. Vantio is product evidence supporting assessment readiness — not a cleared device or a certification.
• Does not: generate your SBOM, threat model, or eSTAR submission — it produces runtime evidence those artifacts and reviewers can draw on.

Get started

Optics is free visibility inside the agent process you wrap. Gate applies the rules you set. Phantom Engine protects Linux hosts you enroll — a Helm DaemonSet on Kubernetes you operate, or a Linux daemon on standalone machines. Talk to sales when you need governance on top.

Sources

• FDA — Cybersecurity in Medical Devices
• Section 524B, Federal Food, Drug, and Cosmetic Act — "cyber device" requirements
• FDA final guidance (February 3, 2026) — QMS considerations and premarket submissions